Rezolute Inc (RZLT): Next-Year EPS Estimate 29.56%
As of 2026-11-12, Rezolute Inc (RZLT) has a next-year EPS growth estimate of 29.56%. Featured in 5 EPS revision reports, most recently on 2026-10-12.
On 2026-11-12, analyst consensus for RZLT's next-year EPS growth shifted from 29.52% to 29.56% — a positive change of 0.04 percentage points. Current-year growth is projected at 6.36%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 29.56%
- EPS growth this year
- 6.36%
- EPS next quarter (est)
- -$0.18
- Last price
- $3.87
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-11-12 | 29.56% | 6.36% | -$0.18 | $3.87 |
| 2026-11-11 | 29.52% | 6.24% | -$0.17 | $4.07 |
| 2026-11-10 | 28.70% | 4.42% | -$0.18 | $4.02 |
| 2026-11-09 | 28.21% | 4.06% | -$0.18 | $3.87 |
| 2026-11-07 | 28.21% | 4.06% | -$0.18 | $3.88 |
| 2026-11-06 | 28.21% | 4.06% | -$0.18 | $3.88 |
| 2026-11-05 | 26.62% | 5.84% | -$0.19 | $3.64 |
| 2026-11-04 | 26.62% | 5.84% | -$0.19 | $3.96 |
| 2026-11-03 | 26.62% | 5.84% | -$0.19 | $4.01 |
| 2026-11-02 | 26.62% | 5.84% | -$0.19 | $3.88 |
| 2026-10-31 | 26.62% | 5.84% | -$0.19 | $3.95 |
| 2026-10-30 | 26.62% | 5.84% | -$0.19 | $3.95 |
| 2026-10-29 | 26.62% | 5.84% | -$0.19 | $4.12 |
| 2026-10-28 | 26.62% | 5.84% | -$0.19 | $4.22 |
| 2026-10-27 | 26.62% | 5.84% | -$0.19 | $4.11 |
| 2026-10-26 | 26.62% | 5.84% | -$0.19 | $3.82 |
| 2026-10-23 | 26.62% | 5.84% | -$0.19 | $3.86 |
| 2026-10-22 | 26.62% | 5.84% | -$0.19 | $3.86 |
| 2026-10-21 | 26.62% | 5.84% | -$0.19 | $3.70 |
| 2026-10-20 | 26.62% | 5.84% | -$0.19 | $3.70 |
| 2026-10-19 | 26.62% | 5.84% | -$0.19 | $3.70 |
| 2026-10-16 | 26.62% | 5.84% | -$0.19 | $3.58 |
| 2026-10-15 | 27.25% | 7.10% | -$0.19 | $3.90 |
| 2026-10-14 | 27.31% | 7.07% | -$0.18 | $4.23 |
| 2026-10-13 | 27.31% | 7.07% | -$0.18 | $4.61 |
| 2026-10-12 | 27.31% | 7.07% | -$0.18 | $4.87 |
| 2026-10-11 | 27.31% | 7.07% | -$0.18 | $4.87 |
| 2026-10-10 | 27.31% | 7.07% | -$0.18 | $4.87 |
| 2026-10-09 | 27.31% | 7.07% | -$0.18 | $4.87 |
| 2026-10-08 | 27.31% | 7.07% | -$0.18 | $4.64 |
Reports Featuring RZLT
- 2026-10-12
Sezzle Leads EPS Revision Screen with 15.6% Jump; NVAX, RZLT Follow
- 2026-10-10
Small-Cap EPS Revision Stocks Surge: SEZL +14%, NVAX +13.6% Lead
- 2026-10-09
PENG Jumps 24.3% on Raised FY27 Outlook; CLF, SEZL Also Surge
- 2026-09-30
IMMP Soars 1688% as EPS Revisions Ignite Biotech Rally; IOVA Jumps 37%
- 2026-09-28
Cracker Barrel Jumps 19.8% on EPS Estimate Surge: CBRL, RZLT, AMAT Lead
Recent News
- Rezolute Reports First Quarter Fiscal 2027 Financial Results and Provides Business UpdateGlobeNewswire
- Rezolute Reports First Quarter Fiscal 2027 Financial Results and Provides Business UpdateGlobeNewswire
- Rezolute Gets FDA Nod For Pre-BLA Meeting Despite Phase 3 Miss Retail Expects Huge ReratingStocktwits
- Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital HyperinsulinismGlobeNewswire
- Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business UpdateGlobeNewswire
- Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business UpdateGlobeNewswire
- Rezolute FDA Review Continues After Phase 3 sunRIZE Study Missed Primary EndpointInvestorsHub
- Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital HyperinsulinismGlobeNewswire
- Rezolute to Participate in Upcoming Investor ConferencesGlobeNewswire
- What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin's Rare-Obesity OpportunityFinanceWire
Screen Performance
Aggregate stats across all 2145 tickers our top-EPS-revision screen has flagged over the past 225 days.
- Median return since detection
- -2.9%
- % of tickers in the green
- 43%
- Median return on winners
- +22.8%
- Large revisions captured
- 2246
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Rezolute Inc's next-year EPS growth estimate?▾
As of 2026-11-12, Rezolute Inc (RZLT) has a next-year EPS growth estimate of 29.56%, based on analyst consensus.
When was the latest EPS estimate revision for RZLT?▾
The most recent revision occurred on 2026-11-12, when analysts adjusted the next-year EPS growth estimate from 29.52% to 29.56%.
What sector and industry does Rezolute Inc belong to?▾
Rezolute Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. RZLT appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Rezolute Inc (RZLT) appears here because it was detected by our daily top-EPS-revision-performer screen.